Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Metastatic Breast Cancer (ASCO) Basic Listing

Updates in Metastatic Breast Cancer
From the ASCO Annual Meeting

Erika Hamilton, MD, Sarah Cannon Research Institute
Videos
Trastuzumab Deruxtecan Maintains Superiority Over Trastuzumab Emtansine Among Patients With HER2-Positive Metastatic Breast Cancer
06/20/2024
Erika Hamilton, MD
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
Erika Hamilton, MD discusses the...
06/20/2024
Oncology
Kevin Kalinsky, MD, Winship Cancer Institute
Videos
Abemaciclib Added to Fulvestrant Improved Progression-Free Survival for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
06/13/2024
Kevin Kalinsky, MD
Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...
Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...
Kevin Kalinsky, MD, shares...
06/13/2024
Oncology
Conference Coverage
Trastuzumab Deruxtecan Remains Superior to Trastuzumab Emtansine Among Patients With HER2-Positive Metastatic Breast Cancer
06/07/2024
According to updated survival results from the DESTINY-Breast03 trial, trastuzumab deruxtecan continues to show superiority over trastuzumab emtansine among patients with HER2-positive metastatic breast cancer.
According to updated survival results from the DESTINY-Breast03 trial, trastuzumab deruxtecan continues to show superiority over trastuzumab emtansine among patients with HER2-positive metastatic breast cancer.
According to updated survival...
06/07/2024
Oncology
Conference Coverage
Trastuzumab Deruxtecan Improves Progression-Free Survival Among Patients With HER2-Low Metastatic Breast Cancer
06/06/2024
According to first results from the phase 3 DESTINY-Breast06 trial, trastuzumab deruxtecan improved survival results among patients with HER2-low and -ultralow, HR-positive metastatic breast cancer.
According to first results from the phase 3 DESTINY-Breast06 trial, trastuzumab deruxtecan improved survival results among patients with HER2-low and -ultralow, HR-positive metastatic breast cancer.
According to first results from...
06/06/2024
Oncology
Conference Coverage
Pembrolizumab Plus Sacituzumab Govitecan for Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer
06/06/2024
According to results from a phase 2 trial, pembrolizumab added to sacituzumab govitecan showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.
According to results from a phase 2 trial, pembrolizumab added to sacituzumab govitecan showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.
According to results from a...
06/06/2024
Oncology
Jane Meisel, MD
Conference Coverage
Antibody Drug Conjugates for Patients With Metastatic Breast Cancer
06/02/2024
Jane Meisel, MD
Jane Meisel, MD, discusses the impact novel antibody drug conjugates have had in the treatment of patients with metastatic breast cancer.
Jane Meisel, MD, discusses the impact novel antibody drug conjugates have had in the treatment of patients with metastatic breast cancer.
Jane Meisel, MD, discusses the...
06/02/2024
Oncology
Conference Coverage
Trastuzumab Deruxtecan With or Without Pertuzumab Shows Promise For Previously Untreated Patients With HER2-Positive Metastatic Breast Cancer
05/28/2024
According to a phase 1b/2 trial, trastuzumab deruxtecan with or without pertuzumab showed promising efficacy among previously untreated patients with HER2-positive metastatic breast cancer, with safety profiles consistent with the known...
According to a phase 1b/2 trial, trastuzumab deruxtecan with or without pertuzumab showed promising efficacy among previously untreated patients with HER2-positive metastatic breast cancer, with safety profiles consistent with the known...
According to a phase 1b/2 trial,...
05/28/2024
Oncology
Yutaka Yamamoto, Kumamoto University Hospital
Videos
Pertuzumab Retreatment Improves OS in HER2-Positive Locally Advanced or Metastatic Breast Cancer
06/08/2023
Yutaka Yamamoto, MD, discusses OS results from the phase 3 PRECIOUS trial evaluating pertuzumab retreatment in patients with HER2-positive locally advanced or metastatic breast cancer.
Yutaka Yamamoto, MD, discusses OS results from the phase 3 PRECIOUS trial evaluating pertuzumab retreatment in patients with HER2-positive locally advanced or metastatic breast cancer.
Yutaka Yamamoto, MD, discusses...
06/08/2023
Oncology
Ian Krop, MD, PhD, Yale Cancer Center
Q&A
Safety and Efficacy of Trastuzumab Deruxtecan for Older Patients with HER2-Positive Metastatic Breast Cancer
06/08/2023
At the 2023 ASCO Annual Meeting, Ian Krop, MD, PhD, discusses the results from an age-specific pooled analysis which evaluated the efficacy and safety of trastuzumab deruxtecan among older patients with HER2-positive metastatic breast cancer.
At the 2023 ASCO Annual Meeting, Ian Krop, MD, PhD, discusses the results from an age-specific pooled analysis which evaluated the efficacy and safety of trastuzumab deruxtecan among older patients with HER2-positive metastatic breast cancer.
At the 2023 ASCO Annual Meeting,...
06/08/2023
Oncology
Erika Hamilton, MD, Sarah Cannon Research Institute
Videos
HER3-DXd for Metastatic Breast Cancer Across Subtypes
06/05/2023
At the 2023 ASCO Annual Meeting, Erika Hamilton, MD, discusses the antibody drug conjugate HER3-DXd, or patritumab deruxtecan.
At the 2023 ASCO Annual Meeting, Erika Hamilton, MD, discusses the antibody drug conjugate HER3-DXd, or patritumab deruxtecan.
At the 2023 ASCO Annual Meeting,...
06/05/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement